3 -3 (53) 2023 — Gulammahmudova D.V. — PATHOGENETIC ASPECTS OF THE DEVELOPMENT OF HYPERANDROGENIA AND A NUMBER OF METABOLIC COMPLICATIONS ASSOCIATED WITH IT AND THEIR CORRECTION IN WOMEN WITH PCOS

PATHOGENETIC ASPECTS OF THE DEVELOPMENT OF HYPERANDROGENIA AND A NUMBER OF METABOLIC COMPLICATIONS ASSOCIATED WITH IT AND THEIR CORRECTION IN WOMEN WITH PCOS

Gulammahmudova D.V. Republican Specialized Scientific and Practical Medical Center of Obstetrics and Gynecology Uzbekistan,

Resume

This review is devoted to the disclosure of the pathogenetic aspects of the development of hyperandrogenism in women with PCOS, by analyzing the literature data published by foreign authors over the past 10 years. The article discusses the conditions that have developed as a result of hyperandrogenism, as well as their pathogenetically substantiated methods of correction. In addition, the results of multicenter studies conducted to evaluate the effectiveness of the progestogen drospirenone in the treatment of correction of hyperandrogenism and metabolic disorders are presented.

Keywords: PCOS, hyperandrogenism, drospirenone

First page

14

Last page

19

For citation: Gulammahmudova D.V. – PATHOGENETIC ASPECTS OF THE DEVELOPMENT OF HYPERANDROGENIA AND A NUMBER OF METABOLIC COMPLICATIONS ASSOCIATED WITH IT AND THEIR CORRECTION IN WOMEN WITH PCOS //New Day in Medicine 3(53)2023 14-19 https://goo.su/B5L95X

LIST OF REFERENCES:

1. Серов В.Н. Гормональная контрацепция // Consilium Medicum, Гинекологическая эндокринология, 2003; 9(5).
2. Кузнецова И.В., Побединский НМ. Новый оральный контрацептив: один из многих или препарат с уникальны­ми свойствами? // Трудный пациент, 2004; 2:11-14.
3. Africander D., Verhoog N, Hapgood J.P. Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception // Steroids, 2011; 76(7):636-652.
4. Breech L.L., Braverman P.K. Safety, efficacy, actions, and patient acceptability of drospirenone/ethinyl estradiol contraceptive pills in the treatment of premenstrual dysphoric disorder // Int J Womens Health, 2010; 9(1):85-95.
5. Marr J., Heinemann K., Kunz M. et al. Ethinyl estradiol 20ug/drospirenone 3mg 24/4 oral contraceptive for the treatment of functional impairment in women with premenstrual dysphoric disorder // Int J Gynaecol Obstet, 2011; 113(2):103-107.
6. Endrikat J.S., MilchevN.P, Kapamadzija A. et al. Bleeding pattern, tolerance and patient satisfaction with a drospirenone-containing oral contraceptive evaluated in 3488 women in Europe, the Middle East and Canada // Contraception, 2009; 79(6):428-432.
7. Sitruk-Ware R, Nath A. Metabolic effects of contraceptive steroids // Rev Endocr Metab Disord, 2011; 12(2):63-75.
8. Anttila L., Bachmann G., Hernadi L. et al. Contraceptive efficacy of a combined oral contraceptive containing ethinyloestradiol 20 ug/drospirenone 3mg administered in a 24/4 regimen: a pooled analysis of four open-label studies // Eur J Obstet GynecolReprodBiol, 2011; 155(2):180-182.
9. Chaiyasit N. Taneepanichskul S. A study of cycle control, side effects and client’s satisfaction of a low dose combined contraceptive containing ethinylestradiol/drospirenone — N24/4 regimen) // J Med Assoc Thai, 2010; 93(5):517-522.
10. Foidart J.M., Wuttke W., Bouw GM. et al. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel // Eur J Contracept Reprod Health Care, 2000; 5(2):124-134.
11. Lello S., Pacifico V, Primavera G. et al. Short-term effect of an estroprogestin containing ethinylestradiol 20 meg + drospirenone 3 mg in 24+4 regimen at hormonal and cutaneous level in ovarian hyperandrogenism // Minerva GinecoL 2010; 62(6):509-513.
12. Bruni Bresciani V Extracontraceptive benefits of EE/DRSP (Yaz) in 24+4 day regimen // Minerva GinecoL, 2010; 62(3):261-266.
13. Lello S., Primavera G., Colonna L. et al. Effects of two estroprogestins containing ethynilestradiol 30 microg and drospirenone 3 mg and ethynilestradiol 30 microg and chlormadinone 2 mg on skin and hormonal hyperandrogenic manifestations // Gynecol Endocrmol, 2008; 24(12):718-723.
14. Rapkm A.J., Sorger S.N., Winer S.A. Drospirenone ethmyl estradiol // Drugs Today (Bare), 2008; 44(2):133-145.
15. Ozdemir S., Gorkemli EL, Gezginc K. et al. Clinical and metabolic effects of medroxyprogesterone acetate and ethinyl estradiol plus drospirenone in women with polycystic ovary syndrome // Int J Gynaecol Obstet, 2008; 103(1):44-49.
16. Joish V.N., Boklage S., Lynen R. et al. Use of drospirenone/ethinyl estradiol (DRSP/EE) among women with acne reduces acne treatment-related resources // JMedEcon, 2011; 5.
17. Koltun W., Maloney J.M., Marr J. et al. Treatment of moderate acne vulgaris using a combined oral contraceptive containing ethinylestradiol 20 ug plus drospirenone 3mg administered in a 24/4 regimen: a pooled analysis // Eur J Obstet Gynecol Reprod Biol, 2011; 155(2):171-175.